Arena Pharmaceuticals Ltd

Filleted Accounts

31 January 2024

Arena Pharmaceuticals Ltd

Registered number: 04135806

Balance Sheet

as at 31 January 2024

N	lotes		2024		2023
			£		£
Fixed assets					
Tangible assets	3		2,555		3,613
Current assets					
Stocks		620,437		788,290	
Debtors	4	749,215		778,158	
Cash at bank and in hand		1,260,045		712,336	
		2,629,697		2,278,784	
Creditors: amounts falling due					
within one year	5	(1,215,035)		(1,130,972)	
Net current assets			1,414,662		1,147,812
Net assets		-	1,417,217	-	1,151,425
Capital and reserves					
Called up share capital			12,000		12,000
Profit and loss account			1,405,217		1,139,425
Shareholders' funds		_	1,417,217	_	1,151,425

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.

Peter Goss

Director

Approved by the board on 29 February 2024

Arena Pharmaceuticals Ltd Notes to the Accounts for the year ended 31 January 2024

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Intangible fixed assets

Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.

Tangible fixed assets

Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:

Freehold buildings over 50 years

Leasehold land and buildings over the lease term

Furniture and office equipment over 4 years

Leasehold office improvements over 7 years or the term of the lease if shorter

Investments

Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first in first out method. The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised.

Debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially

recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

Taxation

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

Provisions

Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

Foreign currency translation

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

Pensions

Contributions to defined contribution plans are expensed in the period to which they relate.

2	Employees	2024 Number	2023 Number
	Average number of persons employed by the company	2	2
3	Tangible fixed assets		
	Plant a		
	machine	ery office	
	ϵ	etc improvements	Total

£

31,321

31,321

£

37,021

37,021

£

5,700

5,700

Depreciation

At 1 February 2023

At 31 January 2024

Cost

	At 1 February 2023	27,708	5,700	33,408
	•		5,700	-
	Charge for the year	1,058	-	1,058
	At 31 January 2024	28,766	5,700	34,466
	Net book value			
	At 31 January 2024	2,555	-	2,555
	At 31 January 2023	3,613	-	3,613
4	Debtors		2024	2023
			£	£
	Trade debtors		746,607	775,076
	Other debtors		2,608	3,082
		-	749,215	778,158
5	Creditors: amounts falling due within one year		2024	2023
,	oreanors, amounts faming due within one year		£	£
	Trade creditors		520,284	481,919
	Amounts owed to group undertakings and underta	kings in which		
	the company has a participating interest		439,609	439,609
	Taxation and social security costs	_	255,142	209,444
		_	1,215,035	1,130,972
		_		

6 Controlling party

The controllong party is Pethel Marali Ltd which is incorporated in England. Its registered office is: Unit 14 Apollo Office Court,

Radclive Road,

Gawcott, Buckingham.

Buckinghamshire.

MK18 4DF

7 Other information

Arena Pharmaceuticals Ltd is a private company limited by shares and incorporated in England. Its registered office is:

Unit 14 Apollo Office Court,

Radclive Road,

Gawcott, Buckingham.

Buckinghamshire.

MK18 4DF

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of

the Companies Act 2006.